ArticleStroke and vascular neurology2026
Clinical features, treatment and long-term outcomes of hemorrhagic moyamoya disease in children: an extensive follow-up study.
Article in Stroke and vascular neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPaediatric hemorrhagic moyamoya disease (hMMD) is rare, with unclear clinical features and long-term outcomes owing to limited data. We comprehensively evaluated the clinical characteristics, prognosis and optimal treatment strategies for pediatric hMMD.
methodsWe screened paediatric patients with hMMD hospitalised between November 2003 and December 2024. Clinical features, treatments and long-term outcomes were retrospectively analysed. Multivariate logistic regression was used to evaluate risk factors for rebleeding and poor prognosis.
resultsDuring the first decade, hemorrhagic events were rare. However, in the second decade, females experienced hemorrhage at age 13-15 years and males at 10-12 years. Over 1103 patient-years, 96 hemorrhagic events occurred. Before encephaloduroarteriosynangiosis (EDAS), seven rehemorrhage instances occurred among 94 patients over 93.2 patient-years of observation. A modified Rankin Scale score ≥3 on admission independently predicted rehemorrhage (p=0.040; OR 5.280; 95% CI 1.083 to 25.739), while early EDAS (within 3 months of the first hemorrhage) significantly reduced this risk (p=0.043; OR 0.107; 95% CI 0.012 to 0.933). EDAS patients had lower rehemorrhage rates compared with their natural history. Anterior choroidal artery dilation and early-onset and delayed-onset posterior cerebral artery involvement increased postoperative complication risk. Early EDAS reduced postoperative complications (p=0.028; OR 0.219; 95% CI 0.057 to 0.845).
conclusionAlthough rare, paediatric hMMD carries a high rebleeding rate. The second decade of life may represent the peak period for bleeding in paediatric patients with MMD, necessitating close monitoring. Early EDAS reduces rebleeding and postoperative complications in hMMD. Compared with the natural course, EDAS safely reduces paediatric rehemorrhage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.